A laboratory scale device for microencapsulation of genetically engineered cells into alginate beads

Gabriel León Fiszman
Unidad de Transferencia Genética,
Instituto de Oncología "A.H. Roffo" - UBA
Av. San Martin 5481
1417 Buenos Aires
Argentina
Tel/fax: 54 11 4580 2813
E-mail: gfiszman@ciudad.com.ar

Armando Luis Karara
Unidad de Transferencia Genética,
Instituto de Oncología "A.H. Roffo" - UBA
Av. San Martin 5481
1417 Buenos Aires
Argentina
Tel/fax: 54 11 4580 2813
E-mail: alkarara@hotmail.com

Liliana Maria Elena Finocchiaro+
Unidad de Transferencia Genética,
Instituto de Oncología "A.H. Roffo" - UBA
Av. San Martin 5481
1417 Buenos Aires
Argentina
Tel/fax: 54 11 4580 2813
E-mail: gglikin@bg.fcen.uba.ar

Gerardo Claudio Glikin**
Unidad de Transferencia Genética,
Instituto de Oncología "A.H. Roffo" - UBA
Av. San Martin 5481
1417 Buenos Aires
Argentina
Tel/fax: 54 11 4580 2813
E-mail: gglikin@bg.fcen.uba.ar

Financial Support: This work was partially supported by grants from FONCYT and CABBIO. A.L.K; G.C.G., L.M.E.F. are members of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. G.L.F. is a fellow of BioSidus S.A.

Keywords: CHO cells, interleukin-2, protein delivery.

On leave of absence from INGEBI-CONICET/FCEN-UBA

The microencapsulation of recombinant cells, widely used for in vitro high-density cell culture, is a novel and potentially cost-effective method of in vivo heterologous protein delivery, where the protein producing cells are immunologically protected from tissue rejection. We report here a simple, reliable and inexpensive laboratory method to generate calcium alginate microcapsules containing genetically engineered, interleukin-2 expressing, Chinese hamster ovary (CHO) cells.

Alginate microencapsulated genetically engineered cells can be used for in vitro recombinant DNA derived protein production as well as for in vivo slow release system of a therapeutic polypeptide. Both applications require the optimisation of alginate beads generation to reproducibly obtain uniformly shaped and sized particles that contain viable producing cells. Such particles allow in vitro high-density cell culture and are also suitable for in vivo intra-tissue injection (Chang et al. 1999).

We report here a simple laboratory method to generate calcium alginate microcapsules containing recombinant human interleukin-2 (rhIL-2) producing Chinese hamster ovary (CHO) cells.

*Corresponding author
Materials and Methods

Cells culture

Cell CHO-K1 [ATCC #: CCL 61] derived cells were grown at 37°C in a humidified atmosphere of 95% air and 5% CO2 in complete medium: IMDM/F12 medium (Gibco-BRL, Carlsbad, CA) supplemented with 8% fetal bovine serum (FBS, Gibco-BRL), 2 mM L-glutamine and 25 mM HEPES buffer (pH 7.4). Serial passages were made by trypsinisation (0.25% trypsin and 0.02% EDTA in PBS) of sub-confluent monolayers.

Device assembly

Air jet driven droplet generation was performed by a simple device assembled in our laboratory as depicted in Figure 1. Briefly, a sterile i.v. administration set for gravity infusion was cut with a scalpel both at the tubing 10 cm before and in the middle of the blister and connected to an air flow output filtered by a parallel pair of 0.22 mm disposable filter units (2.5 cm diameter). Piercing the blister, a regular stainless steel injection 27½-gauge needle was placed with its tip under the air tubing outlet. The needle was then connected to a peristaltic pump driving the cells suspended in the sodium alginate solution. A beaker containing CaCl2 collecting solution was placed about 4-5 cm below the needle tip (Figure 1).

Since sterility is a major concern during cell culture, all the system with the exception of the air compressor pump was placed inside a laminar flow hood.

Cells encapsulation

Encapsulation of genetically engineered CHO cells producing rhIL-2 obtained in our laboratory, we used the assembled system depicted in Figure 1. The air jet flow was usually set between 2 and 10 L/min and cell suspension flow between 120 and 180 ml/h. As expected, microbead diameter decreased with increasing air jet flow (2 to 10 L/min) or decreasing needle diameter (from 19 to 27½-gauge) with bead diameters ranging from 1800 (± 250) to 300 (± 100) mm, respectively.

When encapsulated at an initial density of 3-5x10⁶ cells/ml alginate, capsules containing rhIL-2 secreting CHO cells ranged from 350 to 550 mm in diameter as shown in Figure 2. While alginate and APA capsules showed the typical radially arranged cells (Figure 2a), APA/citrate capsules displayed single centred spheroids (Figure 2b). We did not observe any sign of necrosis within the APA/citrate capsules during the first 30 days of culture.

Alginate as well as APA/citrate capsules resulted resistant to standard manipulations required for laboratory scale culture. The main physical difference between these capsules was the presence of the semi-permeable membrane of APA on the surface of the APA/citrate capsules with a soluble inner filling compared to a semi-solid gel in alginate capsules. Besides the advantage of APA/citrate regarding the immune isolation from any potential humoral host immune response against cells contained into beads, both sorts of capsules displayed a 7- to 8-fold enhancement of transgene expression with respect to monolayer culture, probably due to the three-dimensional configuration of cells growing as multicellular spheroids (data not shown).

As demonstrated by the MTS assay, both alginate and APA/citrate encapsulated cells were maintained in vitro viable for more than 30 days post-encapsulation, producing
A laboratory scale device for microencapsulation of genetically engineered cells into alginate beads

about 200 ng rhIL-2/million cells/day, without significant differences between groups, as determined by ELISA assay (Figure 3). In some long-term in vitro experiments, there was not any significant loss of rhIL-2 expression up to 60 days post-encapsulation (data not shown).

On the other hand, we performed a preliminary experiment in Balb/c mice using intraperitoneally injected alginate capsules that confirmed the in vivo release of the cytokine. One to three days after injection of capsules containing $1 \times 10^6$ cells, we could detect rhIL-2 serum concentrations ranging from 100 to 300 pg/ml.

This work presents a simple, reliable and inexpensive method to microencapsulate cultured cells in the laboratory, using regular molecular biology and biochemistry laboratory equipment and disposable supplies. All the system can be assembled in few minutes and repeatedly used, while maintained under sterile conditions.

Acknowledgments

We thank G. Sobrido and A. Bihary for technical assistance.

References


Figure 1. Schematic diagram of the microcapsule generator.

(a) air compressor,
(b) 0.22 mm filter units,
(c) half blister chamber,
(d) 27½ gauge needle,
(e) peristaltic pump,
(f) CaCl\textsubscript{2} containing solution,
(g) cell suspension containing sodium alginate,
(h) laminar flow hood.
Figure 2. Micrograph of alginate (a) and APA/citrate (b) encapsulated rhIL-2 producing CHO cells respectively at day 15 and 30 post-encapsulation, prepared as described in Materials and Methods with cell suspension flow of 150 ml/h, air jet flow of 7 L/min and needle diameter of 25½-gauge. Horizontal bar: 500 µm.

Figure 3. Long-term rhIL-2 release by encapsulated genetically engineered CHO cells. Cells microencapsulated with alginate (△) or APA/citrate (○) as described in Figure 2, were cultured in T25 flasks containing 2 ml of compacted beads in 10 ml of medium that was renewed every 48 h. Medium culture samples were taken and assayed for rhIL-2 as described in Materials and Methods. The rhIL-2 production was expressed as means ± standard error of the mean of 4 independent experiments measured in duplicate. Results were expressed as mean ± (s.e.m.). Differences between groups were determined by analysis of variance (ANOVA).